Navigation Links
AIDS Research Alliance Gains Exclusive Rights To New Technology from Stanford University
Date:2/8/2010

License will accelerate the development of prostratin—the first in a new class of drugs for the treatment of HIV/AIDS.

(PRWEB) February 8, 2010 --AIDS Research Alliance announced today the signing of a new licensing agreement with Stanford University, transferring exclusive rights of a novel technology developed by Dr. Paul Wender and colleagues of Stanford to AIDS Research Alliance. This new technology (Science, Vol 320, p 649-652, 2 May 2008) will allow AIDS researchers to synthesize the natural compound, prostratin. Early tests conducted at the National Cancer Institute (NCI) and on-going pre-clinical studies conducted by AIDS Research Alliance indicate that prostratin targets latent HIV—the virus not killed by existing anti-HIV therapies. Previously, prostatin had to be collected from natural resources—an expensive and cumbersome process.



“Dr. Wender’s genius removes a major hurdle to the therapeutic development of this promising compound,” said Carolyn H. Carlburg, President & CEO of AIDS Research Alliance. The ability to produce prostratin synthetically will significantly reduce future costs, making prostratin a more viable drug candidate, Carlburg said.

“When used in combination with existing antiretroviral drugs, prostratin may one day help treating physicians eradicate all virus from the body—a feat not yet possible using existing therapies,” stated Dr. Stephen J. Brown, Medical Director at AIDS Research Alliance.

Dr Brown explains: “Current therapies suppress the virus, but they do not completely eradicate virus from the body. Rather, some viral particles lay dormant in pockets or “reservoirs,” avoiding the reach of today’s anti-HIV drugs. When existing treatments are interrupted, the HIV reservoir floods the body with new virus, re-igniting the infection. Thus, no cure for AIDS is possible without emptying the HIV reservoir.”

“AIDS Research Alliance has the only new drug in development that targets the HIV reservoir,” states Dr. Brown. AIDS Research Alliance has been studying how to flush virus from the HIV reservoir for more than a decade, said Dr. Brown.    

If approved by the U.S. Food & Drug Administration (FDA), prostratin would be the first in a new class of drugs and unveil a novel way to treat HIV/AIDS, Carlburg says.    

AIDS Research Alliance on Wikipedia

About AIDS Research Alliance. AIDS Research Alliance is the nation’s only independent, not-for-profit research organization licensed by the National Institutes of Health to develop an anti-HIV drug. AIDS Research Alliance helped to develop about half of current anti-HIV drugs. AIDS Research Alliance conducts research seeking an HIV vaccine and a cure for AIDS. The U.S. Food & Drug Administration conducted a preliminary review of AIDS Research Alliance’s prostratin data in February 2009. Additional pre-clinical studies will continue over the next year.    

###

Read the full story at http://www.prweb.com/releases/2010/02/prweb3532854.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Marijuana ineffective as an Alzheimers treatment: UBC-Vancouver Coastal Health research
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Researcher to track spread of disease, malware and power outages
4. UCSF Researchers Identify Regulator of Human Sperm Cells
5. Octapharma Accepting Applications for Research Grants Through March 31
6. Valentine Tailgate Party for the Girls with Festive Ideas from Beauty Research
7. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
8. Developing a cyberinfrastructure for comparative effectiveness in cancer research
9. Women should be allowed to eat, drink during labor: Queens University researcher
10. Parkinsons disease research uncovers social barrier
11. Fear of Frailty: Research Shows Lack of Activity Threatens Seniors' Independence
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
AIDS Research Alliance Gains Exclusive Rights To New Technology from Stanford University
(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an ... an educational webinar, they will present the line of epMotion automated liquid handling ... easy you can automate everyday pipetting tasks. , Ideal for scientists and lab ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based ... area, is spearheading a regional charity campaign organized to provide support to Christina Upchurch ... of this year, Christina and her children returned from out of town to find ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the ... efforts with its product now available through Jet.com. , After 25 years of ... powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017 AccuGenomics, Inc., a diagnostic company ... announced that the company has provided an AccuKit to ... Carolina at Chapel Hill and to Qura Therapeutics for ... and quantify HIV reservoir and viral expression in human ... HIV Cure Center is a joint initiative between the ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology: